Leading the way to safer medication
 Crosscheck  Recommender

ADCETRIS

Found in: Austria Australia Canada Cyprus Spain France Netherlands Singapore United Kingdom United States

Active Ingredients

#
Chemical substance
Description
1
Brentuximab vedotin

Brentuximab vedotin is an antibody drug conjugate (ADC) that delivers an antineoplastic agent that results in apoptotic cell death selectively in CD30-expressing tumour cells. Nonclinical data suggest that the biological activity of brentuximab vedotin results from a multi-step process. Binding of the ADC to CD30 on the cell surface initiates internalisation of the ADC-CD30 complex, which then traffics to the lysosomal compartment. Within the cell, a single defined active species, MMAE, is released via proteolytic cleavage. Binding of MMAE to tubulin disrupts the microtubule network within the cell, induces cell cycle arrest and results in apoptotic death of the CD30-expressing tumour cell.

ATC Classification

Code
Title
Category
L01XC12
Brentuximab vedotin
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XC Monoclonal antibodies

Product Monographs

Monograph
Type
Country
ADCETRIS Powder for concentrate for solution
MPI, EU: SmPC

Identifiers

Authority
Identifier(s)
FDA, National Drug Code (US)
Identifier(s): 51144-050
Health Products and Food Branch (CA)
Identifier(s): 02401347
Health Sciences Authority (SG)
Identifier(s): 14477P
Pharmaceutical Benefits Scheme (AU)
Identifier(s): 10166C, 10171H, 10172J, 10180T, 11067L, 11073T, 11079D, 11080E, 11086L, 11087M, 11089P, 11096B, 11651F, 11660Q, 11661R, 11664X
Z-Index G-Standaard PRK (NL)
Identifier(s): 103993
Base de données publique des médicaments (FR)
Identifier(s): 68438457
Centro de información online de medicamentos de la AEMPS (ES)
Identifier(s): 112794001, 112794001IP